MINNEAPOLIS, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company dedicated to transforming the lives of people with fluid overload, today reported financial results for the second quarter ended June 30, 2023.
- Revenue of $2.1 million for the second quarter 2023, representing a 14% increase over the prior quarter and a 6% decrease over the prior-year period.
- Utilization, or the number of circuits per console, increased 14% over the same period last year, reflecting an increase in the number of patients treated with the Aquadex therapy.
- By segment, second quarter 2023 revenue in Heart Failure increased approximately 8% over the same period last year, while Critical Care and Pediatrics declined approximately 20% and 5%, respectively. Pediatrics increased 72% from the first quarter.
- Gross margin rate of 55.3% in the second quarter 2023, representing a 730-basis point improvement compared to a gross margin rate of 48% in the same period last year.
- Entered into a Supply and Collaboration Agreement with DaVita Inc. to pilot Aquadex ultrafiltration therapy to treat adult patients with congestive heart failure and related conditions in select U.S. markets.
- Announced the appointment of Mike McCormick to the Board of Directors.
- Cash and cash equivalents of approximately $9 million and no debt as of June 30, 2023.
“We are pleased to report a rebound in our business in the second quarter, with Pediatrics increasing 72% from first quarter, steady growth in the number of patients treated with Aquadex therapy compared to last year, and continued momentum in Heart Failure, supported by growing awareness of our clinical evidence,” said Nestor Jaramillo, President and CEO of Nuwellis. “As we continue to execute on our goal of transforming the lives of patients suffering from fluid overload, we are excited to collaborate with DaVita to potentially help accelerate clinical adoption of our Aquadex ultrafiltration therapy when first-line medical treatments are ineffective. We are currently in active planning for and look forward to initiating the pilot program with DaVita,” concluded Mr. Jaramillo.
Second Quarter 2023 Financial Results
Revenue for the second quarter of 2023 was $2.1 million, compared to $2.2 million in the prior-year period. Results in the quarter were driven by an increase of 14% in circuit sales offset by lower console sales.
Gross margin was 55.3% for the second quarter of 2023, a 730-basis point improvement year over year, primarily due to favorable product sales mix and a $0.1 million non-cash inventory write-off related to the discontinuation of a distribution agreement in the prior-year period.
Selling, general and administrative expenses for the second quarter of 2023 were $4.7 million, compared to $4.3 million in the prior-year period. The increase was primarily due to increased professional fees in the current year quarter.
Second quarter research and development expenses were $1.5 million, compared to $1.1 million in the second quarter of 2022, reflecting higher spend on the new pediatric CRRT device as we ramp up the development effort in preparation for the IDE submission.
Total operating expense of $6.2M was up 15% year over year and down 11% sequentially; this decrease was primarily due to a consolidation of sales territories in the quarter aimed at increasing efficiency.
Net loss for the second quarter of 2023 was $4.8 million, or a loss of $3.65 per share, compared to a net loss of $4.3 million, or a loss of $40.67 per common share, in the prior-year period. The decrease in net loss per share is due to the fact that weighted average shares outstanding for the second quarter of 2023 were approximately 1.3 million, compared to weighted average shares outstanding of approximately 105,000 in the prior-year quarter.
At June 30, 2023, the Company had cash and cash equivalents of approximately $9 million and no debt, with approximately 1.9 million common shares outstanding.
Webcast and Conference Call Information
The company will host a conference call and webcast at 9:00 AM ET today to discuss its financial results and provide an update on the company’s performance.
To access the live webcast, please visit the Investors page of the Nuwellis website at https://ir.nuwellis.com. Alternatively, you may access the live conference call by dialing 1-833-816-1404 (U.S) or 1-412-317-0497 (international) and using the conference ID: 10180182. An audio archive of the webcast will be available following the call on the Investors page at https://ir.nuwellis.com.
About Nuwellis
Nuwellis, Inc. (Nasdaq: NUWE) is a medical technology company dedicated to transforming the lives of patients suffering from fluid overload through science, collaboration, and innovation. The Company is focused on commercializing the Aquadex SmartFlow® system for ultrafiltration therapy. Nuwellis is headquartered in Minneapolis, Minnesota with a wholly owned subsidiary in Ireland. For more information visit www.nuwellis.com or visit us on LinkedIn.
About the Aquadex SmartFlow® System
The Aquadex SmartFlow system delivers clinically proven therapy using a simple, flexible, and smart method of removing excess fluid from patients suffering from hypervolemia (fluid overload). The Aquadex SmartFlow system is indicated for temporary (up to 8 hours) or extended (longer than 8 hours in patients who require hospitalization) use in adult and pediatric patients weighing 20 kg. or more whose fluid overload is unresponsive to medical management, including diuretics. All treatments must be administered by a health care provider, within an outpatient or inpatient clinical setting, under physician prescription, both having received training in extracorporeal therapies.
Forward-Looking Statements
Certain statements in this release may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the new market opportunities and anticipated growth in 2023 and beyond. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risks associated with our ability to execute on our commercialization strategy, the possibility that we may be unable to raise sufficient funds necessary for our anticipated operations, our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, and other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Nuwellis does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
CONTACTS
INVESTORS:
Vivian Cervantes
Gilmartin Group
ir@nuwellis.com
| NUWELLIS, INC. AND SUBSIDIARY | |||||||||||||||||
| Condensed Consolidated Balance Sheets | |||||||||||||||||
| (In thousands, except share and per share amounts) | |||||||||||||||||
| June 30, 2023 | December 31, 2022 | ||||||||||||||||
| ASSETS | (unaudited) | ||||||||||||||||
| Current assets | |||||||||||||||||
| Cash and cash equivalents | $ | 8,896 | $ | 17,737 | |||||||||||||
| Marketable securities | — | 569 | |||||||||||||||
| Accounts receivable | 1,176 | 1,406 | |||||||||||||||
| Inventories, net | 2,733 | 2,661 | |||||||||||||||
| Other current assets | 943 | 396 | |||||||||||||||
| Total current assets | 13,748 | 22,769 | |||||||||||||||
| Property, plant and equipment, net | 875 | 980 | |||||||||||||||
| Operating lease right-of-use asset | 810 | 903 | |||||||||||||||
| Other assets | 120 | 21 | |||||||||||||||
| TOTAL ASSETS | $ | 15,553 | $ | 24,673 | |||||||||||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | |||||||||||||||||
| Current liabilities | |||||||||||||||||
| Accounts payable and accrued liabilities | $ | 2,311 | $ | 2,245 | |||||||||||||
| Accrued compensation | 1,234 | 2,161 | |||||||||||||||
| Current portion of operating lease liability | 206 | 196 | |||||||||||||||
| Current portion of finance lease liability | 14 | 28 | |||||||||||||||
| Other current liabilities | 60 | 58 | |||||||||||||||
| Total current liabilities | 3,825 | 4,688 | |||||||||||||||
| Common stock warrant liability | — | 6,868 | |||||||||||||||
| Operating lease liability | 654 | 760 | |||||||||||||||
| Total liabilities | 4,479 | 12,316 | |||||||||||||||
| Commitments and contingencies | |||||||||||||||||
| Stockholders’ equity | |||||||||||||||||
| Series A junior participating preferred stock as of June 30, 2023 and December 31, 2022, par value $0.0001 per share; authorized 30,000 shares, none outstanding | — | — | |||||||||||||||
| Series F convertible preferred stock as of both June 30, 2023 and December 31, 2022, par value $0.0001 per share; authorized 127 shares, issued and outstanding 127 shares | — | — | |||||||||||||||
| Series I convertible preferred stock as of June 30, 2023 and December 31, 2022, par value $0.0001; authorized 1,049,280, issued and outstanding none and 1,049,280, respectively Preferred stock as of both June 30, 2023 and December 31, 2022, par value $0.0001 per share; authorized 39,969,873 shares, none outstanding | — | — | |||||||||||||||
| Common stock as of June 30, 2023 and December 31, 2022, par value $0.0001 per share; authorized 100,000,000 shares, issued and outstanding 1,864,265 and 536,394 shares, respectively | — | — | |||||||||||||||
| Additional paid-in capital | 289,845 | 279,736 | |||||||||||||||
| Accumulated other comprehensive income: | |||||||||||||||||
| Foreign currency translation adjustment | (24 | ) | (18 | ) | |||||||||||||
| Unrealized gain on marketable securities | — | 56 | |||||||||||||||
| Accumulated deficit | (278,747 | ) | (267,417 | ) | |||||||||||||
| Total stockholders’ equity | 11,074 | 12,357 | |||||||||||||||
| TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | $ | 15,553 | $ | 24,673 | |||||||||||||
See notes to the condensed consolidated financial statements.
| NUWELLIS, INC. AND SUBSIDIARY | ||||||||||||||||||
| Condensed Consolidated Statements of Operations and Comprehensive Loss | ||||||||||||||||||
| (Unaudited) | ||||||||||||||||||
| (In thousands, except per share amounts) | ||||||||||||||||||
| Three months ended June 30, | Six months ended June 30, | |||||||||||||||||
| 2023 | 2022 | 2023 | 2022 | |||||||||||||||
| Net sales | $ | 2,075 | $ | 2,213 | $ | 3,901 | $ | 4,139 | ||||||||||
| Cost of goods sold | 928 | 1,150 | 1,687 | 1,974 | ||||||||||||||
| Gross profit | 1,147 | 1,063 | 2,214 | 2,165 | ||||||||||||||
| Operating expenses: | ||||||||||||||||||
| Selling, general and administrative | 4,664 | 4,257 | 10,154 | 8,669 | ||||||||||||||
| Research and development | 1,505 | 1,107 | 2,933 | 2,213 | ||||||||||||||
| Total operating expenses | 6,169 | 5,364 | 13,087 | 10,882 | ||||||||||||||
| Loss from operations | (5,022 | ) | (4,301 | ) | (10,873 | ) | (8,717 | ) | ||||||||||
| Other income (expense), net | 179 | 17 | 302 | (38 | ) | |||||||||||||
| Change in fair value of warrant liability | — | — | (755 | ) | — | |||||||||||||
| Loss before income taxes | (4,843 | ) | (4,284 | ) | (11,326 | ) | (8,755 | ) | ||||||||||
| Income tax expense | (2 | ) | (2 | ) | (4 | ) | (4 | ) | ||||||||||
| Net loss | $ | (4,845 | ) | $ | (4,286 | ) | $ | (11,330 | ) | $ | (8,759 | ) | ||||||
| Basic and diluted loss per share | $ | (3.65 | ) | $ | (40.67 | ) | $ | (9.23 | ) | $ | (83.12 | ) | ||||||
| Weighted average shares outstanding – basic and diluted | 1,328 | 105 | 1,227 | 105 | ||||||||||||||
| Other comprehensive loss: | ||||||||||||||||||
| Foreign currency translation adjustments | $ | 1 | $ | 1 | $ | (6 | ) | $ | (1 | ) | ||||||||
| Total comprehensive loss | $ | (4,844 | ) | $ | (4,285 | ) | $ | (11,336 | ) | $ | (8,760 | ) | ||||||
See notes to the condensed consolidated financial statements.
| NUWELLIS, INC. AND SUBSIDIARY | |||||||||||||||
| Condensed Consolidated Statements of Cash Flows | |||||||||||||||
| (Unaudited) | |||||||||||||||
| (in thousands) | |||||||||||||||
| Six months ended June 30, | |||||||||||||||
| 2023 | 2022 | ||||||||||||||
| Operating Activities: | |||||||||||||||
| Net loss | $ | (11,330 | ) | $ | (8,759 | ) | |||||||||
| Adjustments to reconcile net loss to cash flows used in operating activities: | |||||||||||||||
| Depreciation and amortization | 169 | 206 | |||||||||||||
| Stock-based compensation expense, net | 378 | 477 | |||||||||||||
| Change in fair value of warrant liability | 755 | — | |||||||||||||
| Net realized gain on marketable securities | (65 | ) | — | ||||||||||||
| Changes in operating assets and liabilities: | |||||||||||||||
| Accounts receivable | 230 | (563 | ) | ||||||||||||
| Inventory, net | (72 | ) | (167 | ) | |||||||||||
| Other current assets | (547 | ) | 76 | ||||||||||||
| Other assets and liabilities | (20 | ) | (152 | ) | |||||||||||
| Accounts payable and accrued expenses | (856 | ) | 117 | ||||||||||||
| Net cash used in operating activities | (11,358 | ) | (8,765 | ) | |||||||||||
| Investing Activities: | |||||||||||||||
| Proceeds from sale of marketable securities | 578 | — | |||||||||||||
| Additions to intangible assets | (99 | ) | — | ||||||||||||
| Purchases of property and equipment | (64 | ) | (81 | ) | |||||||||||
| Net cash provided by (used in) investing activities | 415 | (81 | ) | ||||||||||||
| Financing Activities: | |||||||||||||||
| Proceeds from ATM stock offerings, net | 2,108 | — | |||||||||||||
| Payments on finance lease liability | — | (13 | ) | ||||||||||||
| Net cash provided by (used in) financing activities | 2,108 | (13 | ) | ||||||||||||
| Effect of exchange rate changes on cash | (6 | ) | (1 | ) | |||||||||||
| Net decrease in cash and cash equivalents | (8,841 | ) | (8,860 | ) | |||||||||||
| Cash and cash equivalents - beginning of period | 17,737 | 24,205 | |||||||||||||
| Cash and cash equivalents - end of period | $ | 8,896 | $ | 15,345 | |||||||||||
See notes to the condensed consolidated financial statements.
